John Young - Pfizer President

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  President
Mr. John D. Young is the Group President Pfizer Innovative Health and Angela Hwang of Pfizer Inc, effective January 1, 2018. He was Group President, Global Established Pharma Business from January 2014 until June 2016. President and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Units Regional President for Europe and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until 2009. Director of Johnson Controls International plc.
Age: 54  President Since 2019      
212 733-2323  www.pfizer.com

John Young Latest Insider Activity

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 8.0E-4 % which means that on every $100 spent on asset it made $8.0E-4 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.2094 % implying that it generated $0.2094 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 8.28. Pfizer Tax Assets are expected to significantly decrease based on the last few years of reporting. The last year's Tax Assets were at 5.44 Billion. The current year Revenue to Assets is expected to grow to 0.35, whereas Assets Non Current are expected to decline to about 124.2 B. Pfizer Tax Liabilities is expected to significantly decrease based on the last few years of reporting. The last year's Tax Liabilities was at 18.68 Billion
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer Inc has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

PRESIDENT Since

Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Alok SonigDr Reddys Laboratories
2015
Charles WagnerVertex Pharmaceuticals Incorpor
2019
J RamachandranDr Reddys Laboratories
2016
Joyce LeeZoetis Inc
2012
Paul WeningerPerrigo Company Plc
2015
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Marion McCourtRegeneron Pharmaceuticals
2018
Svend AndersenPerrigo Company Plc
2017
Umang VohraDr Reddys Laboratories
2013
Ronald JanishPerrigo Company Plc
2015
Douglas BoothePerrigo Company Plc
2013
John GrayVertex Pharmaceuticals Incorpor
2019
Thomas FarringtonPerrigo Company Plc
2015
Samiran DasDr Reddys Laboratories
2016
Ganadhish KamatDr Reddys Laboratories
2016
Ian SmithVertex Pharmaceuticals Incorpor
2017
Christopher FenimoreRegeneron Pharmaceuticals
2017
Cartikeya ReddyDr Reddys Laboratories
2016
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Douglas McCorkleRegeneron Pharmaceuticals
2007

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Instant Ratings Now

   

Instant Ratings

Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Currently Active Assets on Macroaxis

TMF   
Purchased over 50 shares of
few hours ago
Traded for 39.69
TQQQ   
Purchased over 20 shares of
few hours ago
Traded for 79.49
TQQQ   
Sold over 20 shares of
few hours ago
Traded for 79.49
TMF   
Sold over 90 shares of
few hours ago
Traded for 39.69
TQQQ   
Sold over 90 shares of
few hours ago
Traded for 79.49
Please check Your Equity Center. Please also try CEO Directory module to screen ceos from public companies around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page